Patent intelligence · US
US 12338450
Gene therapy constructs for treating Wilson disease
Gene therapy constructs for treating Wilson disease
Patent details — US 12338450
- Jurisdiction
- US
- Status
- granted
- Grant date
- Jun 24, 2025
- Expiration
- Jun 19, 2045
- Applicant
- Ultragenyx Pharmaceutical Inc.
- Claims
- 18
- CPC classes
- A61K, A61K48/005, A61K48/0058, A61P
Quick answer
US 12338450 (Gene therapy constructs for treating Wilson disease) is held by Ultragenyx Pharmaceutical Inc.. Status: granted. Granted Jun 24, 2025. Expires Jun 19, 2045 (19 years remaining) — relevant for patent-cliff and LOE planning.
Key facts
- Applicant
- Ultragenyx Pharmaceutical Inc.
- Grant date
- Expiration
- Claims
- 18
- CPC classes
- A61K, A61K48/005, A61K48/0058, A61P, A61P43/00
More from Ultragenyx Pharmaceutical Inc.
Related pharmaceutical patents in our USPTO index.
-
US 12358976
Methods for increasing serum concentration of phosphorous and/or 1,25-hydroxy vitamin d
granted -
US 11944658
Methods of heat inactivation of adenovirus
granted -
US 11771748
Methods for treating tumor-induced osteomalacia
granted -
US 11753369
Creatine prodrugs, compositions and methods of use thereof
granted -
US 11377643
Therapeutics for glycogen storage disease type III
granted -
US 11332438
Creatine prodrugs, compositions and methods of use thereof
granted -
US 11202822
Methods for treating hypophosphatemic disorders
granted
Frequently asked questions
What is US patent 12338450?
US 12338450 (Gene therapy constructs for treating Wilson disease) is held by Ultragenyx Pharmaceutical Inc.. Status: granted. Granted Jun 24, 2025. Expires Jun 19, 2045 (19 years remaining) — relevant for patent-cliff and LOE planning.
Who owns US 12338450?
Ultragenyx Pharmaceutical Inc. is listed as the applicant in USPTO PatentsView records indexed by NovaPharmaNews. We track 23 pharmaceutical patents for this assignee.
When does US 12338450 expire?
Our index shows an expiration date of Jun 19, 2045 (19 years from today). Confirm material dates against USPTO, FDA Orange Book, or qualified counsel before contractual decisions.